tbuckley/cabot-search huggingface dataset:
PWE-044 Outcomes In Massive Colorectal Emr, What Should The Patients Know?
Authors: J Subhani, G El-Sayed
Journal: Gut (2014)

<h3>Introduction</h3> Data from colorectal endoscopic mucosal resection (EMR) of lesions 6 cm and greater is scant. Endoscopists may welcome these lesions as challenges, but what is the longterm outcome and therefore what should patients be advised before consenting to these procedures? <h3>Methods</h3> Prospective data has been collected for over 10 years by a single endoscopist (JMS) on his EMR practice and the database was interrogated for Colorectal resections of flat or sessile polyps, greater or equal to 6 cm. Data for size, Paris classification, assessment, completion in first session, histology, complications (early and late) follow-up duration, recurrence rates and clearance rates. <h3>Results</h3> Of 629 lesions on the database, 154 were 40 mm or greater, and 54 lesions in 54 patients were 60 mm or greater. At endoscopy (for the EMR) 5 lesions were clearly invasive cancer and resection was not attempted. Proceeded to resection in 49 lesions (29 LST-G, 13 Is/Isp, 5 IIa + Is, 2 IIa + IIb). 18 resections were stopped with 12 (24%) of these completed at subsequent session. Complications included 1 perforation treated endoscopically (2%), 4 admissions post procedure (8%), no bleeds and 3 late strictures (6%). Of the 49 resections, 19 had not had follow-up at the time of analysis. 5 were awaiting, 10 had been sent to surgery (3 for cancer, 6 benign lesions due to size/position/access, 1 by misinterpreted histology) 4 due to miscellaneous reasons. 30 had endoscopic follow-up, average duration 737 days and 27/30 &gt; 1 year. Recurrence rates at 3 months were 39%, at 1 year were 27 and 80% were eventually endoscopically cleared. Of the 6 patients still not cleared; 2 had &lt;5 mm recurrence at their last endoscopy, 2 &gt;5 mm recurrence and all four of these are awaiting check endoscopy. The final two patients had surgery, one due to complications of a stricture, one due to failure to complete the resection. Overall in these patients 16% had cancer, with most identified before attempted resection. 37 patients avoided surgery, 76% of those with attempted resections. However for 40% of patients this may require multiple endocopies either for the initial resection or treatment of recurrences or complications. Sustained clearance may take as long as a year to achieve. <h3>Conclusion</h3> Complications were surprisingly uncommon, although patients should be prepared to be admitted after there initial resection. Bleeds in particular were rare compared to 4.5% seen in lesions (in the database) 20–59 mm in size. This data suggests in experienced hands tackling lesions greater or equal to 6cm endoscopically is worthwhile but patients should be aware that in up to 25% of cases surgery still occurs. If surgery is to be avoided multiple endoscopies maybe necessary for cure. <h3>Disclosure of Interest</h3> None Declared.
EVALUATION OF 99m-Tc-GLUCOHEPTONATE TO ESTIMATE TOTAL AND INDIVIDUAL RENAL GLOMERULAR FILTRATION RATE (GFR).
Authors: Stephen E. Long, Wayne L. Thompson, Robert E. Sonnemaker, Bradley K. Pounds
Journal: Clinical Nuclear Medicine (1983)

Long, Stephen E.; Thompson, Wayne L.; Sonnemaker, Robert E.; Pounds, Bradley K. St. Author Information
Improving the Estimating Equation for GFR — A Clinical Perspective
Authors: Matthew R. Weir
Journal: New England Journal of Medicine (2012)

In this issue of the Journal, Inker et al.1 describe a new, combined creatinine–cystatin C estimating equation that provides greater precision and accuracy for classification of the glomerular filtration rate (GFR). This important step forward to enhance accuracy takes advantage of both creatinine-based and cystatin C–based equations. The cystatin C–based equation has an advantage over the creatinine-based equation in that it is less strongly affected by age, sex, and race. Of note, when cystatin C is incorporated into the new equation, race — a variable that is frequently lacking in laboratory and administrative databases — will not be required for . . .
1310 EXPRESSION AND SYSTEMS BIOLOGY ANALYSIS OF T-CELL AND MACROPHAGE SPECIFIC FACTORS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Authors: R. Mehta, M. Keaton, K. Doyle, L. Wang, A. Birerdinc, Z. Goodman, A. Baranova, Z. Younossi
Journal: Journal of Hepatology (2013)
Man died of dehydration after "cascade" of staff failures
Authors: Z. Kmietowicz
Journal: BMJ (2012)

A series of medical and management failures by doctors and nurses led to the death from dehydration of a man who was recovering from a routine hip operation, a coroner has ruled.

Kane Gorny, 22, became so desperate for water that he called the emergency number 999 from his hospital bed the day before he died in May 2009 at St George’s Hospital in Tooting, south London.

At the inquest the deputy coroner Shirley Radcliffe said that “a cascade of individual failures had led to an incredibly tragic outcome.” She recorded a narrative verdict saying that Gorny had died from dehydration contributed to by neglect.

Radcliffe said, “Kane …
Recurrent Hypoglycemia and Retroperitoneal Fibrosarcoma
Authors: J. Marvin Stauffer, George E. Granville, Sam W. Law
Journal: New England Journal of Medicine (1961)

THE occurrence of "Whipple's triad" as a manifestation of certain large, nonpancreatic tumors of mesodermal origin is now firmly established, although the mechanism inducing the episodic hypoglycemia remains undefined. The unusual clinical course and the dramatic relief of hypoglycemia that follows excision of the tumor have resulted in prompt publication of the majority of the reports concerning this association. Meager information is available about the subsequent course of these patients, or about the natural history of this type of tumor.This report presents further information about a patient whose original hypoglycemic attacks were relieved by excision of a large retroperitoneal . . .
Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia
Authors: MJ Brisco, PJ Sykes, E Hughes, S-H Neoh, LE Snell, G Dolman, L-M Peng, IRG Toogood, K Cheney, MS Rice, CJ Story, AA Morley
Journal: Leukemia (2001)
FUNCTIONAL AND STRUCTURAL DIFFERENCES IN FIBROBLASTS FROM ATRIA OF PATIENTS WITH AND WITHOUT ATRIAL FIBRILLATION
Authors: Milanka Petrovic, Zarko Godic, Alisher Holmuhamedov, Kelsey Kraft, Ulugbek Negmadjanov, Larisa Emelyanova, Farhan Rizvi, Gracious Ross, David C. Kress, Ekhson Holmuhamedov, A. Jamil Tajik, Arshad Jahangir
Journal: Journal of the American College of Cardiology (2016)
Abstract 4334: Expression of PID1 correlates with PFS in pediatric medulloblastomas and negatively impacts growth of medulloblastoma, glioblastoma and AT/RT brain tumor cell lines
Authors: Anat Erdreich-Epstein, Xiuhai Ren, Hong Zhou, Matthew Schur, Lingyun Ji, Richard Sposto, Shahab Asgharzadeh
Journal: Cancer Research (2012)

Abstract PID1, discovered in 2006, encodes an adapter protein that contains a phosphotyrosine binding (PTB) domain. Overexpression of PID1 can have inhibitory or proliferative effect, depending on the cell line. In adipocytes and myocytes PID1 inhibits insulin-induced signaling via a yet-unknown mechanism. To date, there are no reports on PID1 effects in cancer. Using quantitative real time RT-PCR of PID1 expression in 78 pediatric medulloblastoma tumors at diagnosis we found that higher PID1 expression correlated with longer progression-free survival (PFS) in multivariate analysis. Similar correlation was found for PID1 variant 1 and variant 2. Interestingly, PID1 was higher in desmoplastic medulloblastomas, which carry better prognosis vs. anaplastic medulloblastomas, which have poorer prognosis. Query of the REMBRANDT database showed that higher PID1 expression was highly correlated with longer overall survival (OS) in gliomas. REMBRANDT also showed that PID1 expression in GBMs (n=228) was 0.47 of the PID1 expression in non-tumor brain (n=28) (p&amp;lt;0.001) and similarly, was lower in GBMs compared to astrocytoma II/III or oligodendroglioma. TCGA similarly showed that PID1 expression in GBM was 0.40 of its expression in non-tumor brain. In tissue culture we found that transient transfection of PID1-tGFP, but not tGFP, inhibited colony formation in GBM (U251, LN229), medulloblastoma (D283MED) and ATRT (CHLA-06-ATRT) cell lines. PID1 expression decreased proliferation (BrdU, 7AAD), increased sub-G0/G1, increased apoptosis (AnnexinV), and increased mitochondrial depolarization (JC1 probe) of GBM, medulloblastoma and/or ATRT cell lines, supporting an inhibitory function for PID1 in these tumors. Studies are currently ongoing into the molecular mechanism that mediates these effects. In summary, our data demonstrate correlation between high PID1 expression and better patient outcome in two different brain tumors: medulloblastomas and gliomas, and inhibitory effect of PID1 in three types of brain tumor cell lines: medulloblastomas, gliomas, and ATRT. This suggests that PID1 may have a functional role in the biology, and possibly in response to therapy, of these three brain tumor types. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4334. doi:1538-7445.AM2012-4334
Case 27-1972
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Stanley Baum, Hubert J. Wolfe
Journal: New England Journal of Medicine (1972)

Presentation of CaseA 61-year-old woman was admitted to the hospital because of abdominal cramps and diarrhea.She had been well until one year previously, when there was the onset of a dull ache in the right upper quadrant of the abdomen that radiated to the left, was unrelated to meals or position and was relieved after the ingestion of antacids. Six months before entry she began to experience borborygmi. One month later the pain radiated toward the left lower quadrant of the abdomen. An upper gastrointestinal series one month thereafter was normal. Three months before entry crampy pain developed . . .
Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia
Authors: Chieh-Lung Cheng, Hsin-An Hou, Ming-Cheng Lee, Chieh-Yu Liu, Jie-Yang Jhuang, Yan-Jun Lai, Chung-Wu Lin, Huan-Yuan Chen, Fu-Tong Liu, Wen-Chien Chou, Chien-Yuan Chen, Jih-Luh Tang, Ming Yao, Shang-Yi Huang, Bor-Sheng Ko, Shang-Ju Wu, Woei Tsay, Hwei-Fang Tien
Journal: Blood (2013)
Soundings: The class reunion
Authors: Kevin Barraclough
Journal: BMJ (2000)

They are strange things, class reunions. There is a certain fascination about them because, in the end, we measure our lives against our contemporaries. Those younger and older are of little interest in this game of comparisons. And so, at the 20 year get together, we find ourselves wandering around in evening dress, surreptitiously watching out of the corner of our eye for the blemishes, the feet of clay. The fellow with the paunch and the lined, careworn face does us all a service. We glance at him and whisper out of the corner of our mouths how old he looks. The initial impression is how little people have changed, until you remember that you are looking at them with eyes that are accustomed to the middleaged face in the shaving mirror.

My wife asked me if I enjoyed the reunion, but that is not quite the right term. It is one of those events, like funerals, that momentarily take you out of the comfortable monotony of the familiar. Each year there is some event that tolls the bell for another year. For me it is returning home on a frosty November night and seeing Orion for the first time in the winter black sky. For my wife, alas, it is doing the tax returns (a flicker of guilt there). But the once a decade event signals the passing of a serious fraction of your life expectancy and causes more than momentary reflection.

So how were they all, these people whose past was briefly entangled with your own? The surprising thing is the extent to which characteristics seem to stay invariant over half a lifetime. There is clearly a law of conservation of feistiness, a law of conservation of awkward English gangliness, a law of conservation of absurd high pitched laughs, and going into too much detail about your past (and possibly a correlation between the latter two variables). And the people who always described themselves in capital lettered cliches, broad brush stroke categories taken from self help books, still do. And then there are the people who, whatever they say, have let you glimpse the uniqueness of them, and you are glad to have met them again.

And overall you drive away in reflective mood, having taken time out of the normal flow of life to consider yourself. Any regrets? As Woody Allen said, “My only regret, is that I'm not someone else.”
Hedgehog inhibits β-catenin activity in synovial joint development and osteoarthritis
Authors: Jason S. Rockel, Chunying Yu, Heather Whetstone, April M. Craft, Katherine Reilly, Henry Ma, Hidetoshi Tsushima, Vijitha Puviindran, Mushriq Al-Jazrawe, Gordon M. Keller, Benjamin A. Alman
Journal: Journal of Clinical Investigation (2016)

Both the WNT/β-catenin and hedgehog signaling pathways are important in the regulation of limb development, chondrocyte differentiation, and degeneration of articular cartilage in osteoarthritis (OA). It is not clear how these signaling pathways interact in interzone cell differentiation and synovial joint morphogenesis. Here, we determined that constitutive activation of hedgehog signaling specifically within interzone cells induces joint morphological changes by selectively inhibiting β-catenin-induced Fgf18 expression. Stabilization of β-catenin or treatment with FGF18 rescued hedgehog-induced phenotypes. Hedgehog signaling induced expression of a dominant negative isoform of TCF7L2 (dnTCF7L2) in interzone progeny, which may account for the selective regulation of β-catenin target genes observed. Knockdown of TCF7L2 isoforms in mouse chondrocytes rescued hedgehog signaling-induced Fgf18 downregulation, while overexpression of the human dnTCF7L2 orthologue (dnTCF4) in human chondrocytes promoted the expression of catabolic enzymes associated with OA. Similarly, expression of dnTCF4 in human chondrocytes positively correlated with the aggrecanase ADAMTS4. Consistent with our developmental findings, activation of β-catenin also attenuated hedgehog-induced or surgically induced articular cartilage degeneration in mouse models of OA. Thus, our results demonstrate that hedgehog inhibits selective β-catenin target gene expression to direct interzone progeny fates and articular cartilage development and disease. Moreover, agents that increase β-catenin activity have the potential to therapeutically attenuate articular cartilage degeneration as part of OA.
A case of delayed bleeding 9 days after endoscopic ultrasound-guided pancreatic pseudocyst drainage
Authors: Tomoaki Matsumori, Akio Katanuma, Hiroyuki Maguchi, Kuniyuki Takahashi, Manabu Osanai, Kei Yane, Toshifumi Kin, Ryo Takaki, Kazuyuki Matsumoto, Katsushige Gon, Akiko Tomonari
Journal: Endoscopy (2014)

Endoscopic ultrasound-guided pancreatic pseudocyst drainage (EUS-PPD) has become a safe and effective procedure for pancreatic pseudocysts. However, postprocedural complication rates of 8.5 % – 20 % have been reported [1] [2] [3] [4]. For delayed complications, only one case of bleeding, which occurred 23 days after EUS-PPD from the transjejunal approach, has been reported [5]. We report a case of bleeding 9 days after EUS-PPD from the transgastric approach.
BM-09 * USE OF NEUROENDOSCOPY TO SAFELY DELIVER INTRATHECAL CHEMOTHERAPY AT THE TIME OF OMMAYA RESERVOIR PLACEMENT
Authors: R. Chu, J. Rudnick, R. Natale
Journal: Neuro-Oncology (2014)

BACKGROUND: For patients with carcinomatous meningitis, treatment needs to be expedited, especially for patients with hematologic malignancies. Using neuroendoscopy as an adjunct at the time of ventricular reservoir placement allows immediate confirmation of catheter placement rather than waiting for a post-operative CT scan and waiting for contact from the surgeon. This confirmation allows delivery of intrathecal chemotherapy at the time of surgery saving the patient delays in chemotherapy delivery and potential side effects of the first chemotherapy delivery, as they are still under general anesthesia. Delay in confirmation of appropriate catheter placement or poor catheter placement delays treatment; this technique also allows the surgeon and oncologist to know definitively that the reservoir is properly positioned and functional at the time of surgery. METHODS: Five patients with carcinomatous meningitis who were candidates for intrathecal chemotherapy were prospectively followed. All of them had a ventricular reservoir placed with neuroendoscopy and immediate delivery of intrathecal chemotherapy. RESULTS: All five of the patients had a reservoir placed without incident. Four of the patients had chemotherapy delivered during surgery without incident. For one patient, there was a pharmacy delay, but the chemotherapy was delivered while the patient was still recovering from anesthesia. There were no complications related to the treatment. CONCLUSIONS: Neuroendoscopy has the power to immediately confirm proper ventricular placement of an Ommaya reservoir and to safely allow the delivery of intrathecal chemotherapy in the operating room. This technique eliminates delays in chemotherapy delivery and is safe.
Abstract 2909: ApoFLIP: A bioactive peptide that restarts the apoptotic machinery in cancer cells
Authors: Taiguang Jin, Alexei Kurakin, Keli Song, Jun-Xia Wang, Tanya Santos, Roya Khosravi-Far
Journal: Cancer Research (2010)

Abstract The cellular factors inhibiting apoptosis are often employed by cancer cells to resist therapy. c-FLIP is an endogenous inhibitor of apoptosis upregulated in many drug resistant tumors. Herein, we show that a peptide derived from c-FLIP is a potent inducer of apoptosis in both in vitro and in vivo cancer models. Mechanistic studies suggest that the apoptogenic peptide of c-FLIP (ApoFLIP) removes the inhibition of pro-apoptotic signaling at the level of activated death receptors by competing c-FLIPL off receptor complexes and clearing the way for activation of the caspase cascade. At the same time, ApoFLIP impairs the pro-survival signaling along the PI3K/Akt pathway by blocking the interaction between the p85 subunit of PI3K and c-FLIPL. The selectivity and apoptogenic potency of ApoFLIP in killing cancer cells suggests that simultaneous targeting of two or more hallmark features of cancer may prove to be a winning therapeutic strategy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2909.
AB0356 Treat to target in early rheumatoid arthritis clinic (eac): remission rates on combination of leflunomide, hydroxychloroquine and methotrexate
Authors: O. Semenova, H. Thompson, S. Kallankara, O. Ogunbambi, Y. Patel, E. Baguley
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The Early Rheumatoid Arthritis Clinic (EAC) was established in 2010 to meet NICE recommendations for treatment of early RA [1]. Locally developed protocol of rapid escalation of treatment with combination of conventional DMARDs was used. High remission and low disease activity (LDA) rates after 1 year of this treatment were reported earlier [2]. In order to control disease activity many patients had to go on combination of Methotrexate (MTX), Hydroxychloroquine (HCQ) and Leflunomide (LEF). <h3>Objectives</h3> To analyse tolerance and efficacy of combination of MTX, HCQ and LEF in EAC patients. <h3>Methods</h3> Patients were adults with diagnosis of RA ≤ 2 years and active disease (DAS &gt; 3.2). Target of treatment was DAS28 remission (DAS28 &lt; 2.6) or LDA (DAS28 &lt; 3.2). We used our protocol for treatment escalation. Therapy started with MTX, with rapid escalation from 15mg to 25 mg per week. If activity persisted, HCQ was added. If DAS28 remained above 3.2, patients were given LEF (10mg, increased to 20mg if necessary). If the disease still remained active, treatment with biologic drugs started. We did not use LEF if patients planned childbirth. The patients were seen every 4-6 weeks, and DAS28 CRP was calculated on each visit. <h3>Results</h3> Of 148 who have continued to attend the EAC, 47 patients (32%) needed treatment with the combination of LEF + HCQ + MTX. The female to male ratio was 1.7:1. At the first visit, all patients had DAS28 &gt; 3.2, and 79% of them were seropositive. 22 of 47 patients (46%) had to stop LEF because of side effects (such as abnormal liver tests, diarrhoea, cytopenia or rash), compliance issues or an onset of a-TNF treatment. All side effects were reversible and not severe. The remaining 25 pts (54%) continued treatment and were still on the MTX+ HCQ + LEF combination at the last visit to the EAC. Almost all patients were on combination of 25mg of MTX (20mg in 3 cases), HCQ 200mg (except 3 cases of intolerance) and LEF 10 mg or 20 mg (12 and 13 patients, respectively). Results of treatment are shown in Table 1. <h3>Conclusions</h3> 54% of the patients tolerated the treatment and among these it was highly effective and resulted in LDA or remission in 24 of 25 patients (96%). Our results agree well with limited available data on LEF+MTX efficacy [3, 4]. In the 46% of patients who could not tolerate the combination all of the side effects were reversible. Due to close monitoring of patients in the EAC, LEF could be stopped at the very first signs of intolerance, with serious side effects avoided. <h3>References</h3> NICE, Feb 2009. Semenova O et al., Annals Rheum. Dis. 2012: 71, S3, 205. Sakellariou GT et al., Clin. Rheumatol. 2011, Sept 9 (Epub ahead of print). Sakellariou GT et al., Rheumatol. Int. 2012, Nov 5 (Epub ahead of print). <h3>Disclosure of Interest</h3> None Declared
FRI0533 Marked differences in occurrence of co-existing diseases at the time of diagnosis of various inflammatory rheumatic diseases
Authors: J. Jyrkkä, E. Lönnroos, H. Kautiainen, H. Koponen, L. J. Virta, T. Pohjolainen, K. Puolakka
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Co-existing diseases increase the burden caused by inflammatory rheumatic diseases (IRDs). Comorbidities may be associated with IRD-related factors or are independent. <h3>Objectives</h3> To examine the occurrence of comorbidities among incident patients with several IRDs. <h3>Methods</h3> Finland has a general sickness insurance covering the entire population. Patients with certain chronic diseases (e.g., chronic cardiac and pulmonary diseases, inflammatory bowel disease, IRDs, etc.) are entitled to special reimbursement of medications if their condition meets defined criteria. These patients are recorded in the national registry of the Social Insurance Institution. This registry was used to identify all incident cases of IRDs between 1 Jan 2000 and 31 Dec 2007. Data on their possible co-existing chronic diseases at the time of diagnosis were gathered from the same source. <h3>Results</h3> During the 8-year period, 25 994 incident patients over 16 years of age with IRDs were identified. Of them, 14 878 (57%) had rheumatoid arthritis (RA) (63% RF-positive, 68% female), 3686 (44% female) spondylarthropathy (ICD 10-codes M45 and M46, SpA), 2942 (48% female) psoriatic arthritis (PsA), 802 (55% female) chronic reactive arthritis (ReA), and 3610 (65% female) chronic undifferentiated arthritis (UA). Table shows occurrence per cent of principal groups of co-existing diseases at the time of diagnosis of these rheumatic conditions. <h3>Conclusions</h3> Occurrence of comorbidities differs markedly between various IRDs at the time of diagnosis. <h3>Disclosure of Interest</h3> None Declared